Charlie Yang is a Senior Analyst in Equity Research on the US Biopharmaceuticals team, covering Large/SMid Cap Biotech and Major Pharma. Prior to joining BofA, Yang was an Equity Analyst at Morgan Stanley, covering Major Pharma and Large/SMid Cap Biotech. Before that, he was a strategic project manager at GLG. He has a Ph.D in Anatomy and Neurobiology from Boston University School of Medicine and a BS from the University of California, Irvine. He is based in New York.